To further characterize the role of HMGB1 in RIPC-induced protection from AKI, we used a specific inhibitor (BoxA, 300 μg/mouse i.p.), which represents an inactive part of the HMGB1 molecule and blocks ligand binding of endogenous HMGB1 in vivo (32). This evidence concerns the gene HMGB1 and acute kidney injury.